These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1132 related articles for article (PubMed ID: 17007924)

  • 1. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
    Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
    Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
    Bishop JD; Nien WL; Dauphinee SM; Too CK
    J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway.
    Lee KW; Yook JY; Son MY; Kim MJ; Koo DB; Han YM; Cho YS
    Stem Cells Dev; 2010 Apr; 19(4):557-68. PubMed ID: 19642865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.
    Brunn GJ; Williams J; Sabers C; Wiederrecht G; Lawrence JC; Abraham RT
    EMBO J; 1996 Oct; 15(19):5256-67. PubMed ID: 8895571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
    Dutton A; Reynolds GM; Dawson CW; Young LS; Murray PG
    J Pathol; 2005 Mar; 205(4):498-506. PubMed ID: 15714459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-threonine regulates G1/S phase transition of mouse embryonic stem cells via PI3K/Akt, MAPKs, and mTORC pathways.
    Ryu JM; Han HJ
    J Biol Chem; 2011 Jul; 286(27):23667-78. PubMed ID: 21550972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The relationship of mTOR signaling pathway and histone acetylation in human gastric cancer cell lines].
    Sun DF; Fang JY; Zhang YJ; Tian XQ; Zhu HY; Li EL; Gu WQ; Shen GF
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):387-91. PubMed ID: 17680526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
    Quan P; Moinfar F; Kufferath I; Absenger M; Kueznik T; Denk H; Zatloukal K; Haybaeck J
    Anticancer Res; 2014 Jun; 34(6):2883-97. PubMed ID: 24922651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR regulates vascular smooth muscle cell differentiation from human bone marrow-derived mesenchymal progenitors.
    Hegner B; Lange M; Kusch A; Essin K; Sezer O; Schulze-Lohoff E; Luft FC; Gollasch M; Dragun D
    Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):232-8. PubMed ID: 19074484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling.
    Nakao T; Shiota M; Tatemoto Y; Izumi Y; Iwao H
    J Pharmacol Sci; 2007 Dec; 105(4):334-41. PubMed ID: 18057776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck.
    Liu FY; Zhao ZJ; Li P; Ding X; Zong ZH; Sun CF
    Br J Oral Maxillofac Surg; 2010 Jun; 48(4):291-6. PubMed ID: 19615795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
    Janus A; Linke A; Cebula B; Robak T; Smolewski P
    Anticancer Drugs; 2009 Sep; 20(8):693-701. PubMed ID: 19584709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
    Zeng Z; Sarbassov dos D; Samudio IJ; Yee KW; Munsell MF; Ellen Jackson C; Giles FJ; Sabatini DM; Andreeff M; Konopleva M
    Blood; 2007 Apr; 109(8):3509-12. PubMed ID: 17179228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.